Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.

Automated summary

This vaccine formulation induced strong systemic neutralizing antibodies in mice, providing complete protection against a lethal challenge and lung injury, as well as virus clearance from the lungs. Additionally, the adjuvanted vaccine elicited systemic and local anti-Spike IgA, which could be a key feature for a COVID-19 vaccine.